Clinical trials: Influenza A, Influenza B
SARS-CoV-2, Influenza A
POC Performance Evaluation of LumiraDx SARS-CoV-2 Ag Ultra and SARS-CoV-2 & Flu A/B Tests.
This is a prospective multicenter study conducted to evaluate the performance of the LumiraDx SARS-CoV-2 Ag Ultra test in detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and LumiraDx SARS-CoV-2 \& Flu A/B…
- Conditions
- SARS-CoV-2, Influenza A, Influenza B, COVID-19
- Trial name
- PURSUE (NCT05728970)
- Testing
- LumiraDx SARS-CoV-2 Ag Ultra, LumiraDx SARS-CoV-2 & Flu A/B
- Where
- 10 sites in United States
- Volunteers
- 716 people, healthy volunteers welcome
- Sponsor
- LumiraDx UK Limited
Influenza A Infection, Influenza B Virus Infection
Age Related Differences in Respiratory Immune Responses in Influenza Virus Infection
The goal of this observational study is to understand immune responses to viral airway infection in adults, including the elderly.
- Conditions
- Influenza A Infection, Influenza B Virus Infection, SARS CoV 2 Infection, RSV Infection
- Trial name
- NPA-DC (NCT06401720)
- Where
- 5 sites in Sweden
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
COVID-19, Influenza A
Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.
This study is designed as a prospective, multicentric, sample collection study. The collected samples will be used for diagnostic research, product development and validation of the Panbio™ COVID-19/ Flu A\&B Rapid Panel for the…
- Conditions
- COVID-19, Influenza A, Influenza Type B
- Trial name
- NCT05354115
- Testing
- Nasal and Nasopharyngeal Sampling of the Panbio™ COVID-19/ Flu A&B Rapid Panel
- Where
- United States
- Volunteers
- 676 people
- Sponsor
- Abbott Rapid Dx
Group A, C Polysaccharide Meningitis, Type b Haemophilus Influenza
Immunogenicity and Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Infants and Children
Haemophilus influenzae is an important pathogen which can cause primary infection and respiratory viral infection in infants and leaded to secondary infections.
- Trial name
- NCT01428908
- Testing
- A+C+hib Conjugate Vaccine, A+C Vaccine, Hib vaccine
- Where
- China
- Volunteers
- 2,394 people
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Severe Sepsis
Symphony IL-6 Study in Patients at Risk of Severe Sepsis
Symphony IL-6 is a device that quantitates human IL-6 by fluorescence enzyme immunoassay (FEIA) from whole-blood specimens. Use of Symphony IL- 6 removes the need for plasma separation before testing.
- Trial name
- NCT05665153
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Bluejay Diagnostics, Inc.
Influenza A, Influenza B
Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp)
TreatResp is a double-blind, individually randomized, multi-centre adaptive platform trial. TreatResp aims to establish an adaptive platform trial aimed at evaluating the clinical- and cost-effectiveness, practical challenges…
- Conditions
- Influenza A, Influenza B, SAR-CoV-2, Acute Respiratory Infections (ARIs)
- Trial name
- TreatResp (NCT07314905)
- Testing
- Baloxavir
- Where
- Canada
- Volunteers
- 264 people
- Sponsor
- Unity Health Toronto
Pulmonary Disease, Chronic Obstructive, Bronchospasm
Prophylactic Efficacy of Relenza Against Influenza A and B
In response to the European regulatory authorities, GSK is conducting a post-marketing observational study to assess the efficacy of Relenza when used as prophylaxis against influenza. SPECIFIC AIMS 1.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Bronchospasm, Influenza, Human, Asthma
- Trial name
- NCT01156701
- Testing
- Receiving a prescription of Relenza for prophylaxis, No prophylaxis with Relenza
- Volunteers
- 171,705 people
- Sponsor
- GlaxoSmithKline
Hematologic Disorder
Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)
The goal of this clinical research study is to learn if lenalidomide can increase the level of immunoglobulins (parts of the blood that may help to improve the immune system's function) and/or will improve the protective effect…
- Trial name
- NCT01924169
- Testing
- Lenalidomide, Influenza Vaccine, Pneumovax Vaccine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
SARS-CoV-2 Infection, Influenza A
SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings
The Metrix COVID/Flu Test will be evaluated for use in Point-of-Care and Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein.
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza B
- Trial name
- NCT06191393
- Testing
- Aptitude Medical Systems Metrix COVID/Flu Test
- Where
- 3 sites in United States
- Volunteers
- 614 people
- Sponsor
- Aptitude Medical Systems
Influenza, Human, Influenza
Clinical Performance of the Diassess Influenza A and B Test
The primary objective of this study is device feasibility of the Diassess Influenza A and B Test
- Conditions
- Influenza, Human, Influenza, Flu
- Trial name
- NCT03035396
- Testing
- Diassess Influenza A and B Test
- Where
- United States
- Volunteers
- 567 people
- Sponsor
- Diassess Inc.
Safety Issues, Effect of Drug
ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus Infection
The goal of this Phase II/III study is to investigate the safty and efficacy of ADC189 tablets in adolescents and adults with influenza A virus infection/influenza B virus infection.
- Trial name
- ADC (NCT06342921)
- Testing
- 15 mg ADC189, 45 mg ADC189
- Where
- China
- Volunteers
- 749 people
- Sponsor
- Jiaxing AnDiCon Biotech Co.,Ltd
Influenza
Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone
This is a Phase 1b, randomized study in healthy younger (18-50 years) and older (51-70 years) adults to evaluate the safety, tolerability, and immunogenicity of a prime-boost vaccination regimen with an investigational plasmid…
- Trial name
- NCT01498718
- Testing
- DNA vaccine, TIV
- Where
- 4 sites in United States
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
This Phase 3 study is a randomized, observer-blind study of MF59-adjuvanted influenza vaccine (aQIV or aTIV) compared with a non-adjuvanted influenza vaccine (QIV or TIV) in adults ≥65 years of age.
- Trial name
- NCT06087640
- Testing
- aQIV or aTIV, QIV or TIV
- Where
- 255 sites in United States, Australia and 19 more
- Volunteers
- 38,769 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Influenza A
Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adoption of Protective Behaviors Related to ILI
The goal of this prospective, digital randomized controlled trial is to evaluate the effectiveness of a predictive ILI detection algorithm and associated alerts during influenza season for adults living in the contigent United…
- Conditions
- Influenza, Influenza A, Influenza B, COVID-19
- Trial name
- NCT06229444
- Testing
- ILI Predictive Alerts, Reactive Content, and Proactive Content, ILI Predictive Alerts, Reactive Content, Proactive Content
- Where
- United States
- Volunteers
- 17,043 people, healthy volunteers welcome
- Sponsor
- Evidation Health
Influenza
A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination
To describe the safety during days 0 to 21 following injection of the 2003-2004 formulation of the inactivated, split-virion influenza vaccine Fluzone® in subjects aged 18-59 years and subjects aged ≥ 60 years.
- Trial name
- NCT00835926
- Testing
- Influenza virus vaccine
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009
This study will compare influenza vaccine responses in monozygotic and dizygotic twins.
- Trial name
- NCT01987349
- Testing
- Fluzone® (intramuscular), FluMist® (intranasal)
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Stanford University
RNA Virus Infections, Viral Infection COVID-19
Effectiveness of Ammonium Chloride in Reducing Viral Load
This is a prospective, double-blind, randomized, comparative effectiveness pilot study evaluating the effect of a sustained-release ammonium chloride formulation (ACF) on viral load dynamics in adult patients with mild or…
- Conditions
- RNA Virus Infections, Viral Infection COVID-19, Influenza A and B
- Trial name
- ACTEarly (NCT07254052)
- Where
- 2 sites in Greece
- Volunteers
- 32 people
- Sponsor
- National and Kapodistrian University of Athens
Immune Response
Immune Responses Induced by Different Licensed Influenza Vaccines
The goal of this research is to find out how the body's immune system responds to different manufacturer's "flu" vaccines.
- Trial name
- NCT00902278
- Testing
- Flulaval, Fluvirin, Fluzone
- Where
- United States
- Volunteers
- 193 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
COVID - 19, Influenza A
Evaluation of COVID-19 and Flu A/B 3 in 1 Combo Rapid Test
This observational study aims to evaluate the diagnostic performance of an investigational Influenza A/B and COVID-19 test in patients presenting with signs and symptoms of respiratory infection.
- Conditions
- COVID - 19, Influenza A, Influenza B
- Trial name
- NCT07190131
- Testing
- Investigational Flu A/B And Covid-19 Diagnostic Test
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 588 people
- Sponsor
- iHealth Labs inc
Healthy
Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children.
The purpose of this study is to determine the efficacy of the liquid formulation of CAIV-T against culture confirmed influenza illness in healthy children aged at least 6 months and less than 36 months.
- Trial name
- NCT00192400
- Testing
- CAIV-T
- Volunteers
- 2,160 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC